Biswas R, Vonderhaar B K
Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland 20892.
Cancer Res. 1989 Nov 15;49(22):6295-9.
The rat lymphoma cell line Nb2 is highly prolactin responsive in terms of growth. Estrogens are without effect in these cells that lack the estrogen receptor. The growth stimulation by lactogenic hormones is effectively inhibited by antiestrogens, such as tamoxifen and nafoxidine, at concentrations as low as 10(-10) M. The growth inhibition is partially reversed by replacement of the antiestrogens by prolactin. Nb2 cells contain estrogen-noncompetitive specific antiestrogen binding sites on their membranes that bind tamoxifen with an average Kd of 3.1 X 10(-10) M. Addition of antiestrogens to the binding reaction inhibits lactogenic hormone binding to membrane-bound receptors. The order of affinities of various antiestrogens (tamoxifen, nafoxidine, 2-(4-tert-butyl-phenoxy)ethyl diethylamine hydrochloride, and LY117018) for the antiestrogen binding sites parallels the order of their potencies as growth and lactogen binding inhibitors. These data suggest that antiestrogens, possibly acting through the antiestrogen binding sites, may function as antilactogens.
大鼠淋巴瘤细胞系Nb2在生长方面对催乳素高度敏感。雌激素对这些缺乏雌激素受体的细胞没有作用。抗雌激素药物,如他莫昔芬和萘福昔定,在低至10^(-10) M的浓度下就能有效抑制催乳激素对生长的刺激作用。用催乳素替代抗雌激素药物可部分逆转生长抑制作用。Nb2细胞在其细胞膜上含有雌激素非竞争性特异性抗雌激素结合位点,该位点与他莫昔芬结合的平均解离常数为3.1×10^(-10) M。在结合反应中加入抗雌激素药物会抑制催乳激素与膜结合受体的结合。各种抗雌激素药物(他莫昔芬、萘福昔定、2-(4-叔丁基苯氧基)乙基二乙胺盐酸盐和LY117018)对抗雌激素结合位点的亲和力顺序与其作为生长和催乳素结合抑制剂的效力顺序相似。这些数据表明,抗雌激素药物可能通过抗雌激素结合位点发挥作用,充当抗催乳素。